TScan Therapeutics' Existing Cash Resources Of $162.8M Along With The $161.4M Net Proceeds Received From Its April 2024 Underwritten Public Offering Will Provide Cash Runway Into The Fourth Quarter Of 2026
TScan Therapeutics' Existing Cash Resources Of $162.8M Along With The $161.4M Net Proceeds Received From Its April 2024 Underwritten Public Offering Will Provide Cash Runway Into The Fourth Quarter Of 2026
TScan Therapeutics的現有1.628億美元現金資源以及其2024年4月承銷公開發行獲得的1.614億美元淨收益將爲2026年第四季度提供現金流
TScan Therapeutics' Existing Cash Resources Of $162.8M Along With The $161.4M Net Proceeds Received From Its April 2024 Underwritten Public Offering Will Provide Cash Runway Into The Fourth Quarter Of 2026
TScan Therapeutics的現有1.628億美元現金資源以及其2024年4月承銷公開發行獲得的1.614億美元淨收益將爲2026年第四季度提供現金流
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。